ORCL 83-day bearish forecast — Nov 15, 2026

  • Bias: Bearish
  • Timeframe: 83 days (made Nov 15, 2026, target date Feb 5, 2027)
  • Price at analysis: $125.35
  • Price target: $119.00
  • Expected range: $104.00 – $134.00
  • Result: Pending — graded after the close on Feb 5, 2027

Get a free AI analysis of ORCL today

ORCL technical analysis chart

Analysis

TECHNICAL INDICATORS

  • RSI (14): 47.11, just under the 50 midline. It is recovering from 37.7 on Nov 5 but has faded from 49.4 on Nov 11. It shows no oversold or overbought condition, and momentum is flat. [Neutral]
  • 20 EMA: Not supplied. Price at $125.35 is well below the EMA 50 ($133.79), which is falling and acts as resistance. A 20 EMA would sit near the BB midline (~$126.6), so price is hovering just under it. [Bearish]
  • MACD: Line -3.68 is above signal -4.21, a small bullish crossover on Nov 12-13. Both lines are deeply negative and below zero, so this is a shallow relief signal inside a bearish structure. The histogram has just turned slightly positive. [Neutral]
  • Bollinger Bands (20): Upper $140.66, lower $112.53, midline ~$126.6. Price is at the midline, after bouncing from the lower band area (~$115) on Nov 5-10. The bands are narrower than in the summer, and the downward slope of the bands and midline confirms the downtrend. [Neutral]
  • CMF (20): -0.032, inside the ±0.05 neutral zone. It has improved from -0.159 on Oct 26, so selling pressure is easing, but it has not turned into accumulation. [Neutral]
  • ADX (14): 12.7 and falling, so the trend is very weak and range-like. −DI (23.9) is above +DI (21.8), a marginal bearish edge. The DIs were equal on Nov 11 and bears have since regained a slight lead. [Weak Trend, slight bearish tilt]
  • Volume: 22.55M, near average. The recent high-volume spikes (late Oct) were on a sharp up-bar and a sharp reversal, which shows volatile two-way trading, not clear accumulation. Down days have not been on capitulation volume. [Neutral]

Moving-average structure is clearly bearish:

  • Price is below the EMA50 ($133.79), SMA50D ($136.67), EMA200 ($155.13), SMA200D ($154.11) and VWAP ($159.68).
  • EMA50 is below EMA200, and SMA50D is below SMA200D (a death cross is in place).
  • All of these are still declining.

DIVERGENCES & TRENDS

  • Price vs. RSI: Price made a lower low (~$115) while RSI held around 37-38, near its prior lows, so there is no strong divergence. RSI has not gone below 30 since the summer, which shows weaker downside momentum than the earlier May-July selloff, though not a confirmed bullish divergence.
  • MACD: The bullish line/signal crossover is early and occurs below zero. Such crossovers in downtrends often fail near the falling EMA50.
  • CMF: Recovering from -0.16 toward neutral, which is a mild improvement.
  • ADX/DI: ADX has dropped from the mid-20s to 12.7, so trend strength is fading. This points to consolidation in the lower part of a long-term downtrend. Bears are still marginally ahead.
  • Trend: Lower highs since May (~$250, then ~$170, ~$160, ~$145) and lower lows, with price below a falling 200-day average. The long-term trend is down.
  • Crossovers: The death cross (SMA50D below SMA200D) and EMA50 below EMA200 are established. The only recent bullish crossover is MACD.

CHART PATTERNS

  • Descending Triangle (primary, bearish continuation): Lower highs (~$160 in Aug, ~$145 in Oct) press against a horizontal support zone of ~$115-118 (July lows, Nov 5 and Nov 10 closes). A decisive close below ~$115 would project a measured move toward ~$100-105, in line with the pattern's height.
  • Triple Bottom / Double Bottom (alternative, bullish): The $115-118 zone has been tested three times. A reversal here would need a break above ~$128-134 and the EMA50, and confirmation is still missing.
  • Bearish flag character: The Oct-Nov bounce and consolidation under the falling EMA50 resembles a weak counter-trend rally within the downtrend.
  • Net, the structure leans toward a bearish continuation but is not decisive because ADX is low.

POTENTIAL SCENARIOS

  • Scenario 1: Bearish Support Break / Descending Triangle Resolution — Rallies fail below the falling EMA50 (~$133) and price breaks the repeatedly tested $115-117 support, with the death-cross structure and −DI dominance continuing. Trigger: daily close below $115 (lower BB ~$112.5 is already in play). Target: $103-108, with an extension to ~$100. Invalidation: daily close above $134 (EMA50) with rising volume. (45% probability)
  • Scenario 2: Bullish Triple-Bottom Relief Rally — The $115 support holds a third time, the MACD cross extends and CMF turns positive. Price rallies toward the upper BB and the SMA50D. Trigger: close above $134 with CMF above +0.05. Target: $140-145 (upper BB / Oct high), with a stretch to ~$155 (200-day averages). Invalidation: close below $115. (30% probability)
  • Scenario 3: Neutral Range Consolidation — With ADX near 12, price oscillates between ~$115 support and ~$134-140 resistance without resolving. Trigger: failure of either a break below $115 or a break above $134. Target: $120-130. Invalidation: a decisive close outside the $112-141 band area. (25% probability)

PRICE TARGETS

For the 83-day horizon (through ~Feb 6, 2027), the expected range uses ~24% width: $104.00 to $134.00 = $30.00 width, or 23.9% of $125.35, which fits the 18-30% guidance for 61-180 days.

  • Target Price: $119.00 (a slightly bearish drift from $125.35, consistent with the downtrend, the break risk at $115 and a likely rejection at the EMA50)
  • Expected Range: $104.00 to $134.00
  • Key Levels: Support at $115.00, Resistance at $133.79

OVERALL BIAS

OVERALL BIAS: BEARISH - Price sits below every major moving average with a death cross in place, −DI is above +DI, and lower highs press against the $115-118 support. The MACD cross and neutral CMF/RSI limit conviction, but the bearish scenario carries the most probability.

This is educational analysis and not financial advice.

More ORCL predictions

See every ORCL prediction and its track record

Get a free AI analysis of ORCL today

AI-generated technical analysis for education only — not financial advice.